CN104302633B - 苯并[1,3]二氧杂环己烯衍生物和它们作为lpar5 拮抗剂的应用 - Google Patents
苯并[1,3]二氧杂环己烯衍生物和它们作为lpar5 拮抗剂的应用 Download PDFInfo
- Publication number
- CN104302633B CN104302633B CN201380025938.2A CN201380025938A CN104302633B CN 104302633 B CN104302633 B CN 104302633B CN 201380025938 A CN201380025938 A CN 201380025938A CN 104302633 B CN104302633 B CN 104302633B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- dioxine
- benzo
- dicyclohexyl
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COc1cc(Oc(cc2)cc(C(*3)(C4CCCCC4)C4CCCCC4)c2OC3C(O)=O)ccc1 Chemical compound COc1cc(Oc(cc2)cc(C(*3)(C4CCCCC4)C4CCCCC4)c2OC3C(O)=O)ccc1 0.000 description 5
- ZTMLYBVFVDTKGY-UHFFFAOYSA-N CCN(CC)c1ccc(C(C2CCCCC2)(C2CCCCC2)OC(C(O)=O)O2)c2c1 Chemical compound CCN(CC)c1ccc(C(C2CCCCC2)(C2CCCCC2)OC(C(O)=O)O2)c2c1 ZTMLYBVFVDTKGY-UHFFFAOYSA-N 0.000 description 1
- ISFWOCTVLCBYSR-UHFFFAOYSA-N CN(C)c1ccc(C(C2CCCCC2)(C2CCCCC2)OC(C(O)=O)O2)c2c1 Chemical compound CN(C)c1ccc(C(C2CCCCC2)(C2CCCCC2)OC(C(O)=O)O2)c2c1 ISFWOCTVLCBYSR-UHFFFAOYSA-N 0.000 description 1
- CVXDJDQOTBCABM-UHFFFAOYSA-N COc1ccc(C(C2CCCCC2)(C2CCCCC2)OC(C(O)O)O2)c2c1 Chemical compound COc1ccc(C(C2CCCCC2)(C2CCCCC2)OC(C(O)O)O2)c2c1 CVXDJDQOTBCABM-UHFFFAOYSA-N 0.000 description 1
- KDKJWPODDXVGNR-UHFFFAOYSA-N OC(C(OC(C1CCCCC1)(C1CCCCC1)c1c2)Oc1ccc2Br)=O Chemical compound OC(C(OC(C1CCCCC1)(C1CCCCC1)c1c2)Oc1ccc2Br)=O KDKJWPODDXVGNR-UHFFFAOYSA-N 0.000 description 1
- MXFVAFNZRSVMKQ-UHFFFAOYSA-N OC(C(OC(C1CCCCC1)(C1CCCCC1)c1c2)Oc1ccc2S(N1CCCC1)=O)=O Chemical compound OC(C(OC(C1CCCCC1)(C1CCCCC1)c1c2)Oc1ccc2S(N1CCCC1)=O)=O MXFVAFNZRSVMKQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305553.5 | 2012-05-18 | ||
| EP12305553 | 2012-05-18 | ||
| PCT/EP2013/060172 WO2013171318A1 (en) | 2012-05-18 | 2013-05-16 | Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104302633A CN104302633A (zh) | 2015-01-21 |
| CN104302633B true CN104302633B (zh) | 2016-09-07 |
Family
ID=48468297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380025938.2A Expired - Fee Related CN104302633B (zh) | 2012-05-18 | 2013-05-16 | 苯并[1,3]二氧杂环己烯衍生物和它们作为lpar5 拮抗剂的应用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9221784B2 (enExample) |
| EP (1) | EP2850070B1 (enExample) |
| JP (1) | JP6238970B2 (enExample) |
| KR (1) | KR20150016304A (enExample) |
| CN (1) | CN104302633B (enExample) |
| AU (1) | AU2013261719B2 (enExample) |
| BR (1) | BR112014028189A2 (enExample) |
| CA (1) | CA2871545A1 (enExample) |
| ES (1) | ES2649438T3 (enExample) |
| IL (1) | IL235219A (enExample) |
| MX (1) | MX354521B (enExample) |
| PL (1) | PL2850070T3 (enExample) |
| RU (1) | RU2647727C2 (enExample) |
| SG (1) | SG11201407216YA (enExample) |
| SI (1) | SI2850070T1 (enExample) |
| WO (1) | WO2013171318A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200215085A1 (en) * | 2017-07-19 | 2020-07-09 | Uti Limited Partnership | Method to Abate Acute Airway Hypersensitivity and Asthma Attacks |
| KR20250140741A (ko) | 2024-03-19 | 2025-09-26 | 경북대학교 산학협력단 | 알룰로스를 포함하는 혈전 예방 또는 개선용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4056540A (en) | 1974-01-01 | 1977-11-01 | Bristol-Myers Company | 4-Phenyl-1,3-benzodioxans |
| US4056450A (en) | 1975-06-30 | 1977-11-01 | M & T Chemicals Inc. | Continuous detinning system |
| FR2424914A2 (fr) * | 1978-05-03 | 1979-11-30 | Roussel Uclaf | Nouveaux derives de (1-3) benzodioxine, un procede pour leur preparation et leur application comme medicaments |
| SE445553B (sv) * | 1978-05-03 | 1986-06-30 | Roussel Uclaf | /4h/-1,3-bensodioxan-2-karboxylsyraderivat |
| GB8310407D0 (en) * | 1982-05-12 | 1983-05-25 | Ici Plc | 1 3 - dioxan -5- ylalkenoic acids |
| FR2704857B1 (fr) * | 1993-05-07 | 1995-06-23 | Adir | Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| CN101124226A (zh) * | 2004-05-07 | 2008-02-13 | 记忆药物公司 | 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途 |
| WO2010042600A2 (en) * | 2008-10-08 | 2010-04-15 | The Uab Research Foundation | Photo-activatable therapeutic agents and methods of using |
-
2013
- 2013-05-16 SG SG11201407216YA patent/SG11201407216YA/en unknown
- 2013-05-16 BR BR112014028189A patent/BR112014028189A2/pt not_active Application Discontinuation
- 2013-05-16 PL PL13723767T patent/PL2850070T3/pl unknown
- 2013-05-16 MX MX2014014012A patent/MX354521B/es active IP Right Grant
- 2013-05-16 WO PCT/EP2013/060172 patent/WO2013171318A1/en not_active Ceased
- 2013-05-16 RU RU2014151240A patent/RU2647727C2/ru not_active IP Right Cessation
- 2013-05-16 AU AU2013261719A patent/AU2013261719B2/en not_active Ceased
- 2013-05-16 SI SI201330853T patent/SI2850070T1/en unknown
- 2013-05-16 EP EP13723767.3A patent/EP2850070B1/en not_active Not-in-force
- 2013-05-16 CN CN201380025938.2A patent/CN104302633B/zh not_active Expired - Fee Related
- 2013-05-16 KR KR20147033844A patent/KR20150016304A/ko not_active Withdrawn
- 2013-05-16 ES ES13723767.3T patent/ES2649438T3/es active Active
- 2013-05-16 CA CA 2871545 patent/CA2871545A1/en not_active Abandoned
- 2013-05-16 US US14/401,041 patent/US9221784B2/en not_active Expired - Fee Related
- 2013-05-16 JP JP2015512073A patent/JP6238970B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-20 IL IL235219A patent/IL235219A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL235219A (en) | 2017-03-30 |
| EP2850070B1 (en) | 2017-08-23 |
| KR20150016304A (ko) | 2015-02-11 |
| RU2014151240A (ru) | 2016-07-10 |
| BR112014028189A2 (pt) | 2017-06-27 |
| MX354521B (es) | 2018-03-08 |
| AU2013261719A1 (en) | 2014-12-18 |
| ES2649438T3 (es) | 2018-01-12 |
| WO2013171318A1 (en) | 2013-11-21 |
| MX2014014012A (es) | 2015-02-12 |
| SI2850070T1 (en) | 2018-01-31 |
| CA2871545A1 (en) | 2013-11-21 |
| SG11201407216YA (en) | 2014-12-30 |
| PL2850070T3 (pl) | 2018-01-31 |
| JP2015517515A (ja) | 2015-06-22 |
| RU2647727C2 (ru) | 2018-03-19 |
| AU2013261719B2 (en) | 2017-07-27 |
| US20150111889A1 (en) | 2015-04-23 |
| CN104302633A (zh) | 2015-01-21 |
| EP2850070A1 (en) | 2015-03-25 |
| JP6238970B2 (ja) | 2017-11-29 |
| US9221784B2 (en) | 2015-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA003993B1 (ru) | Сульфонамиды для лечения заболеваний, связанных с эндотелином | |
| JP2006515345A (ja) | オキシム誘導体および薬学的活性剤としてのそれらの使用 | |
| CZ297544B6 (cs) | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy | |
| CN116262724A (zh) | 新型氧代吡啶类化合物及其制备方法和用途 | |
| JP2013509376A (ja) | ブラジキニン受容体アンタゴニストとして有用な２−アリール−プロピオンアミド誘導体およびそれらを含有する医薬組成物 | |
| US9346762B2 (en) | Pyrazole derivatives and their use as LPAR5 antagonists | |
| US9315492B2 (en) | Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof | |
| CN104302633B (zh) | 苯并[1,3]二氧杂环己烯衍生物和它们作为lpar5 拮抗剂的应用 | |
| JP2025510512A (ja) | Ｌｐａ受容体活性と関連する状態の処置のための化合物および組成物 | |
| JP2015521183A (ja) | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 | |
| JP6461113B2 (ja) | ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用 | |
| EP2860176A1 (en) | Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof | |
| JP2000086659A (ja) | オクタヒドロピリド［１，２―ａ］ピラジン誘導体 | |
| KR20140120903A (ko) | 여포 자극 호르몬수용체의 아고니스트로서 중수소화 티아졸리디논 유사체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160907 Termination date: 20200516 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |